Trial Profile
Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 28 Apr 2020 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 06 Nov 2018 Planned number of patients changed from 175 to 94.